Andrew Paul Mazar

Insider Reports History

Location
Fort Worth, TX
Signature
/s/ Paul Lytle, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Andrew Paul Mazar:

Company Role Class Num Shares Value Price $ Report Date Ownership
Monopar Therapeutics Chief Scientific Officer, Director Common Stock 166,667 $56,700 $0.3402 31 Mar 2022 Indirect
Monopar Therapeutics Chief Scientific Officer, Director Restricted Stock Units 88,792 $30,207 $0.3402 31 Mar 2022 Direct
Monopar Therapeutics Chief Scientific Officer, Director Common Stock 22,125 $7,527 $0.3402 31 Mar 2022 Direct
ACTUATE THERAPEUTICS, INC. Chief Operating Officer Common Stock 127,250 12 Aug 2024 Direct
ACTUATE THERAPEUTICS, INC. Chief Operating Officer Employee Stock Option (right to buy) 110,346 01 Apr 2025 Direct

Insider Reports Filed by Andrew Paul Mazar

Symbol Company Period Transactions Value $ Form Type Role Filing Time
ACTU ACTUATE THERAPEUTICS, INC. 01 Apr 2025 2 $0 4 Chief Operating Officer 02 Apr 2025, 13:43
ACTU ACTUATE THERAPEUTICS, INC. 12 Aug 2024 0 $0 3 Chief Operating Officer 12 Aug 2024, 21:47
MNPR Monopar Therapeutics 31 Mar 2022 3 -$1,201 4 Chief Scientific Officer, Director 01 Apr 2022, 17:28
MNPR Monopar Therapeutics 02 Feb 2022 2 $0 4 Chief Scientific Officer, Director 04 Feb 2022, 18:38
MNPR Monopar Therapeutics 01 Jan 2022 3 -$2,154 4 Chief Scientific Officer, Director 04 Jan 2022, 13:49
MNPR Monopar Therapeutics 31 Dec 2021 3 -$1,785 4 Chief Scientific Officer, Director 04 Jan 2022, 13:40
MNPR Monopar Therapeutics 30 Sep 2021 3 -$2,294 4 Chief Scientific Officer, Director 01 Oct 2021, 19:31
MNPR Monopar Therapeutics 30 Jun 2021 3 -$5,548 4 Chief Scientific Officer, Director 02 Jul 2021, 17:11